Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03033043 · ClinicalTrials.gov registry record · NA

Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection

A NA study of Aortic Dissection Type B, sponsored by Bolton Medical.

Active
Registry status
NA
Development phase
56
Enrollment target
20
Study locations

NCT03033043 is a NA study of Aortic Dissection Type B that is active but no longer recruiting, run by Bolton Medical. The registered enrollment target is 56 participants. The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03033043, a NA study of Aortic Dissection Type B, is active but no longer recruiting, sponsored by Bolton Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
56 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.

Conditions Studied

Interventions

  • DEVICE Relay Pro Stent-Graft

Study Locations (20)

Connecticut

  • Hartford Hospital - Hartford
  • Yale School of Medicine - New Haven

Ohio

  • University Hospitals - Cleveland
  • Cleveland Clinic Foundation - Cleveland

Pennsylvania

  • University of Pennsylvania Medical Center / Penn Presbyterian - Philadelphia
  • Lankenau Medical Center - Wynnewood

Virginia

  • Sentara Heart Hospital - Norfolk
  • Carilion Roanoke Memorial Hospital - Roanoke

California

  • USC Department of Surgery - Los Angeles

Colorado

  • University of Colorado Denver - Aurora

District of Columbia

  • Medstar Washington Hospital Center - Washington D.C.

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2017-12-14
Est. Completion 2026-11
Phase NA

Sponsor

Bolton Medical

10 total trials

What the Registry Record Tells You About NCT03033043

The ClinicalTrials.gov registry entry for NCT03033043 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bolton Medical, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aortic Dissection Type B appearing as the primary indexed condition, and to 1 intervention - of which Relay Pro Stent-Graft is the first listed.

NCT03033043 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Connecticut, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03033043 about?

NCT03033043 is a clinical study titled "Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection". This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.

What is the current status of trial NCT03033043?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2017-12-14. Estimated completion is 2026-11.

What conditions does trial NCT03033043 study?

This clinical trial studies the following conditions: Aortic Dissection Type B.

What interventions are being tested in trial NCT03033043?

The interventions under investigation include: Relay Pro Stent-Graft (DEVICE).

Who is sponsoring clinical trial NCT03033043?

This trial is sponsored by Bolton Medical, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03033043 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.